This is a routine board appointment with no immediate trading implications. Monitor for any future strategic shifts in R&D direction that Dr. Reed's presence might influence, but no catalyst is present here.
Price Chart
Executive Summary
Madrigal Pharmaceuticals appointed John C. Reed, M.D., Ph.D., a top R&D executive from Johnson & Johnson, to its Board of Directors, expanding the board from eight to nine members. This is a routine governance move that adds significant scientific and industry expertise but provides no new financial data or strategic catalysts for the stock.
Key Facts
- Board expanded from 8 to 9 members with the appointment of John C. Reed, M.D., Ph.D.
- Dr. Reed is Executive Vice President, Innovative Medicine, R&D at Johnson & Johnson and a member of its Executive Committee.
- Dr. Reed will receive an annual cash retainer of $50,000, a $10,000 committee fee, and an initial equity grant valued at $675,000 (50% options, 50% RSUs).
- Dr. Reed was appointed to the Science and Technology Committee.
- No material financial data, guidance, or operational updates were provided in this filing.
Financial Impact
No financial impact from this board appointment. Director compensation is standard and immaterial relative to a $12.4B market cap.
Risk Factors
- No material risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-055962 |
| Document: pressrelease-boardappointm.htm | 0001628280-26-055962 |
| Document: 0001628280-26-055962-index-headers.html | 0001628280-26-055962 |
| Document: 0001628280-26-055962-index.html | 0001628280-26-055962 |
| Document: 0001628280-26-055962.txt | 0001628280-26-055962 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 12, 2026 7w ago | 8-K | $536.20 $533.12 | ▼ −0.57% | ▲ +1.32% | $496.64 (−7.38%) |
Jul 30, 2026 9w ago | 8-K | $493.11 $543.69 | ▲ +10.26% | ▲ +6.29% | $496.64 (+0.71%) |
May 22, 2026 18w ago | Insider Cluster | $524.28 $520.00 | ▼ −0.82% | ▲ +1.13% | $496.64 (−5.27%) |
May 6, 2026 21w ago | 8-K | $539.73 $488.15 | ▼ −9.56% | ▼ −12.34% | $496.64 (−7.98%) |
Apr 28, 2026 22w ago | 8-K | $518.58 $515.96 | ▼ −0.51% | ▼ −6.55% | $496.64 (−4.23%) |
Apr 22, 2026 23w ago | Press Release | $529.14 $511.82 | ▼ −3.27% | ▼ −6.44% | $496.64 (−6.14%) |
Mar 19, 2026 28w ago | Press Release | $441.16 $527.11 | ▲ +19.48% | ▲ +10.16% | $496.64 (+12.57%) |
Mar 2, 2026 30w ago | Insider Cluster | $435.62 $505.34 | ▲ +16.00% | ▲ +23.94% | $496.64 (+14.01%) |
Mar 2, 2026 30w ago | Insider Cluster | $435.62 $505.34 | ▲ +16.00% | ▲ +23.94% | $496.64 (+14.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access